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Abstract
Background: The adjuvant treatment for patients with isolated stromal invasion after radical hysterectomy and
pelvic lymph node dissection (PLND) in FIGO stage IB1 and IIA1 cervical carcinoma has not been established. This
study assessed the survival outcomes and recurrent patterns in this particular group of patients treated with
chemotherapy or radiation-based adjuvant therapy.
Methods: The records 133 IB1 and IIA1 postoperative cervical carcinoma patients with histopathology-confirmed
isolated deep stromal invasion (DSI) without any other unfavorable pathological finding between June 2010 and
March 2013 were analyzed. Sixty-five patients received postoperative adjuvant four to six cycles of cisplatin-based
chemotherapy (CT group) and Sixty-eight received postoperative received postoperative adjuvant radiotherapy (RT
group). Treatment-related toxicities were evaluated and disease-free survival (DFS) and overall survival (OS) were
analyzed using Kaplan-Meier estimates and statistical significance was determined using the log-rank test.
Results: With a median follow-up of 33.7 months (range 10–62 months), RT group had a significantly improved in DFS
rate (P = 0.044), but there was no significant difference in overall survival (P = 0.437). Upon further analysis, patients with
outer 1/3 to full-thickness invasion in chemotherapy group exhibited significantly higher recurrence rates compared to
the radiotherapy group. Leukocytopenia, nausea and vomiting were the most frequent short-term complications of
chemotherapy, whereas colitis/proctitis and cystitis were more frequent in the radiotherapy group (P = 0.000 respectively).
No significant differences were found regards to other acute toxicities, including hemoglobin, platelets and ALT/AST,
colitis/proctitis, cystitis and dermatitis (P = 0.000 respectively). Fewer late severe side effects in the chemotherapy group
were observed compared with the radiation group and significant differences were found at colitis/proctitis, cystitis and
dermatitis (P = 0.000 respectively).
Conclusion: Compared to chemotherapy alone, postoperative RT to FIGO stages IB1 and IIA1 cervical carcinoma patients
with isolated DSI can reduce risk of recurrence and with acceptable morbidity.
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Background
Cervical cancer remains one of the most common can-
cers in women worldwide and more than 85 % of the
cancer burden occur in developing countries, around a
quarter of the new cases in the world are diagnosed in
China every year. The management paradigms for cer-
vical cancer are well established with preference of sur-
gery in early-stage disease patients [1]. After surgery,
there are some pathological findings that were regarded
as being at high risk of recurrence and warrant neces-
sary postoperative treatment, which including positive
pelvic nodes, surgical margin and/or positive parame-
trium [2–4]. Moreover, if patients with a tumor that is
confined to the cervix that display combination of
intermediate-risk factors such as a large tumor, lympho-
vascular space involvement (LVSI), or deep stromal inva-
sion (DSI), are considered to be at risk of recurrence and
also need postoperative pelvic radiotherapy (RT).
One frequently encountered situation at clinical prac-
tice, however, was that only one of these intermediate
risk pathology factors, such as isolated deep stromal in-
vasion without LVSI+ and larger tumor diameter was
presented. For this situation, radiotherapy as an adjuvant
treatment after radical hysterectomy has been widely
used. Moon et al. evaluated the potential benefit of post-
operative radiotherapy in women with full-thickness
cervical stromal invasion (FTSI) without any other un-
favorable pathological finding and found that postopera-
tive radiotherapy could improve pelvic control with
acceptable morbidity [5]. As an alternative, the utility of
chemotherapy (CT) has also been suggested for postop-
erative adjuvant therapy. For example Takeshima re-
ported that at their institute, CT alone has been used as
postoperative adjuvant therapy for cervical cancer and
treatment results suggest the potential role of adjuvant
chemotherapy alone for patients with intermediate- and
high-risk cervical cancer [6].
Although it has been suggested that adjuvant CT com-
bined with radical hysterectomy and systematic lymph-
adenectomy has a survival benefit [7] and patients after
operation often received adjuvant chemotherapy or
radiotherapy in deferent institution, the role of adjuvant
treatment has not been extensively investigated. Thus,
the purpose of the present study was to evaluate the
survival outcomes and in patients with isolated deep
stromal invasion treated with chemotherapy and radio-
therapy after radical hysterectomy and PLND in stages
IB1 and IIA1 cervical carcinoma.
Methods
Patients and procedures
The Institutional Review Board of the Cancer Hospital
of Zhengzhou University reviewed and approved this
study ((approval No.15CT079) and medical records were
obtained with informed consent of all patients. The in-
clusion criteria were: (1) age 35–75 years old; (2) with
definite histological diagnosis; (3) normal liver and renal
function; (4) acceptable cardiovascular pulmonary and
other major organ functions. Exclusion criteria includ-
ing: (1) age < 36 or > 75 years; (2) any lung, liver, or
cardiovascular pulmonary and other major organ dys-
functions; (3) with other high risk factors include para-
metrial extension, positive pelvic nodes and margins (4)
combined these intermittent risk pathology factors; (5)
pathologically proven distant metastasis; (6) with any
component of neuroendocrine or clear cell differenti-
ation within the tumor wit and another coexisting malig-
nancy. A total of 1577 FIGO stage IB1 and IIA1 cervical
cancer patients treated by radical abdominal hysterec-
tomy and lymphadenectomy with/without bilateral
salpingo-oophorectomy between June 2010 and March
2013 was performed. 1414 patients with positive pelvic
LN or combined with other pathologic risk factor were
excluded.143 patients met the including criteria were
identified and ten patients without complete follow-up
data were excluded. Of the included 133 patients, 65 pa-
tients received postoperative chemotherapy (chemother-
apy group) and 68 patients received postoperative pelvic
radiotherapy (RT group) and concurrent weekly cisplatin
as sensitizer.
Chemotherapy
Sixty-five patients received platinum-based chemother-
apy. The paclitaxel plus cisplatin regimen was given
every 3 weeks, which consisted of paclitaxel 135 mg/m2
over 3 h IV on day 1 and cisplatin 60 mg/m2, 2-h i.v. in-
fusion for 4–6 cycles. Toxicity was graded according to
the National Cancer Institute common toxicity criteria.
Granulocyte colony stimulating factor (GCS-F) was sub-
cutaneously administered at the dose of 5 μg/kg daily in
case of WBC less than 4000/μl until recovery. Red blood
cell transfusion was administered in case of hemoglobin
level below 7 gr/dl.
External beam RT
Sixty-eight patients after 4 weeks of radical surgery re-
ceived whole pelvis irradiation with 3D conformal radio-
therapy (3D-CRT). The median radiation dose of 50 Gy
was delivered in 1.8 to 2.0 Gy fractions once daily for
5 days per week. The pelvic treatment fields generally
extended superiorly to include L5. When lateral fields
were used, the posterior border encompassed S2. CTV
(clinical target volume) was defined as an area of poten-
tial microscopic disease and included supravaginal por-
tion, paracervical tissue, common iliac lymph nodes,
internal and external iliac lymph nodes, obturator
lymph nodes and sacral lymph nodes. Patients in RT
groups also received platinum-based concurrent
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chemotherapy, which consisted of weekly 40 mg/m2
intravenous cisplatin.
Follow-up evaluation
Patients were evaluated every three months for the two
year, every six months during the following three years,
and annually thereafter. At each visit, bimanual examin-
ation and physical examination, and vaginal cytology
were performed for the detection of lower genital tract
neoplasia. Scans of the abdomen and pelvic region were
conducted by ultrasound or CT scan. Suspected cases of
recurrent disease were confirmed by biopsy whenever
possible. Disease-free survival (DFS) and Overall survival
(OS) was calculated from the date of diagnosis until the
date of occurrence of disease progression and to the date
of death or, for surviving patients, to the date of last
follow-up. The cause of deaths due to disease, directly or
indirectly from treatment-related complications, and un-
known causes was confirmed by correspondence, tele-
phone or medical record review. Surviving patients were
censored on the date of last follow-up.
Statistical analysis
Clinical characteristics of patients, local control, survival,
toxicities, and the dosimetric parameter were compared
using Fisher exact test for frequencies and the Mann–
Whitney U test for continuous variables between the
two groups. The probabilities of DFS, OS were calcu-
lated using the Kaplan-Meier method. Differences be-
tween groups were analyzed using the Log-rank statistic.
Statistical significance was defined at a level of P < 0.05.
All analyses were performed using SPSS version 17.0
(SPSS Inc., Chicago, IL).
Results
Patient and tumor characteristics
The median age of all patients was 49.0 years (range 36–
73) in chemotherapy group and 50.8 years (range 37–75)
in RT group. Comparison of between these two groups
revealed no statistically significant differences in terms
of age (P = 0.141), FIGO stage (P = 0.474), histology sub-
type (P = 0.525), grade (P = 0.556), depth of stromal inva-
sion (P = 0.698) and the number of retrieved lymph
nodes (P = 0.303). The patient characteristics are sum-
marized in Table 1.
Complications
Acute toxicities, measured from the initiation of treat-
ment to 90 days after completion, were graded according
to the National Cancer Institute Common Toxicity
Criteria for Adverse Events, version 3.0. Adverse events
90 days after the completion of treatment were graded
according to the Radiation Therapy Oncology Group
(RTOG) late toxicity scale. Leukocytopenia, nausea and
vomiting were the most frequent short-term complica-
tions at chemotherapy group (P = 0.003 and 0.020),
whereas colitis/proctitis and cystitis complications were
more frequent in the radiotherapy group (both P = 0.000).
Platelets, hemoglobin and ALT/AST were common in
both group, and no statistically significant difference was
found (P = 0.198 and 0.151 and 0.776 respectively). The
acute toxicities are summarized in Table 2.
As for the incidence of late toxicities in chemotherapy
and radiation therapy group according to Radiation
Therapy Oncology Group-European Organization for
Research and Treatment of Cancer (RTOG/EORTC) cri-
teria. Fewer late severe side effects in the chemotherapy
group were observed compared with the radiation group
and significant differences were found at colitis/proctitis,
cystitis and dermatitis (P = 0.000, 0.000 and 0.000, re-
spectively), but no patients experienced grade 3/4 skin
reaction and treatment-related fistula formation and
small-or large-bowel obstruction were recorded in the
RT group as shown in Table 3.
Clinical outcomes and impact of treatment on survival
The median follow-up for patients was 33.7 months
(range 10–62 months). All time intervals were measured
from the time of diagnosis. In the chemotherapy group,
59 of 65 patients were alive without evidence of disease
and one patients died from cervical cancer and five
(7.7 %) patients developed a recurrence after a median
time of 30.8 months (range, 10–58 months) and received
brachytherapy, pelvic or paraaortic RT. Of these five
patients with recurrence, three patients had vaginal
Table 1 Clinical and pathologic characteristics at chemotherapy
group and radiotherapy group
Characteristics CT (n = 65) RT (n = 68) P value
Age (years) 49.0(36–73) 50.8(37–75) 0.141
BMI
FIGO stage



















Squamous cell carcinoma 59(90.8 %) 63(92.6 %)
Adenocarcinoma 6(9.2 %) 5(7.4 %)
Grade 0.556
1 22 (33.8 %) 20 (29.4 %)
2 27(41.5 %) 29(42. 6 %)
3 16(24.6 %) 19(27.9 %)
Number of retrieved lymph nodes 22.8 ± 4.7 23.6 ± 3.9 0.303
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recurrences; one patient with peripheral pelvic wall re-
currence and one patient had distant failure and died. In
RT group, after a median time of 36.4 months (range,
14–62 months), one (1.5 %) out of 68 patients relapsed
in the lung was observed and died.
Statistically significant difference was observed when
different adjuvant treatment was compared. DFS at
chemotherapy group and the radiotherapy group were
77.4 % and 96.2 % according to Kaplan-Meier analysis
and DFS rates in radiotherapy group were significantly
increased compared to those in the chemotherapy group
(P = 0.030) (Fig. 1). In order to find underlying variable
that makes the difference, we stratified the analysis ac-
cording to the stromal invasion depth and it revealed
more details. It is the subgroup of patients with invasion
greater outer to full-thick invasion among radiotherapy
group were significantly increased compared to those in
the chemotherapy groups (P = 0.014) (Fig. 2). This cor-
relation between status of invasion depth and recurrence
was enhanced when we found that the recurrence oc-
curred almost in patients with full-thick invasion. The
five-year OS rate for the patients treated with CT and
RT group were 95.5 % and 95.7 %, respectively, and no
statistically significant difference was found (P = 0.783).
Discussion
The goal of postoperative radiotherapy (PORT) in pa-
tients with a combination of minor risk factors accord-
ing to the initial report of Gynecologic Oncology Group
(GOG) randomized trial was to reduce the risk of recur-
rence and improve survival in patients. But, due to the
limitedness of access to radiotherapy and the on the dis-
cretion of the gynecologic oncologist [8], cervical cancer
patients with postoperative intermediate pathologic risk
factor in many countries and clinical centers often be
Table 2 Incidences of acute toxicities at chemotherapy and
radiotherapy group according to National Cancer Institute
Common Toxicity Criteria for Adverse Events, version 3.0
Grade CT (n = 65) RT (n = 68) P value
Leukocytes 0.003
1 6(9.2 %) 15(22.1 %)
2 2436.9 %) 34(50.0 %)
3 32(49.2 %) 15(22.1 %)
4 3(4.6 %) 4(5.9 %)
Hemoglobin 0.198
1 30(46.2 %) 39(57.4
2 31 (47.7 %) 26(38.2 %)
3 4(6.2 %) 3(4.4 %)
4 0(0 %) 0(0 %)
Platelets 0.151
1 38(58.5 %) 47(69.1 %)
2 20(30.8 %) 18(26.5 %)
3 6(9.2 %) 3(4.4 %)
4 1(1.5 %) 0 (0 %)
ALT/AST 0.776
1 7(10.8 %) 3(4.4 %)
2 1(1.5 %) 0(0 %)
3 0(0 %) 0(0 %)
4 0(0 %) 0(0 %)
Nausea/vomiting 0.020
1 27(41.5 %) 41(60.3 %)
2 24(36.9 %) 20(29.4 %)
3 14(21.5 %) 7(10.3 %)
4 0(0 %) 0(0 %)
Colitis/Proctitis 0.000
1 64(100 %) 40(58.8 %)
2 1(1.5 %) 25(36.8 %)
3 0(0 %) 3(4.4 %)
4 0(0 %) 0(0 %)
Cystitis 0.000
1 65(100 %) 49(70.1 %)
2 0(0 %) 15(22.1 %)
3 0(0 %) 4(5.9 %)
4 0(0 %) 0(0 %)
Table 3 Incidences of late toxicities in chemotherapy and
radiotherapy group according to RTOG/EORTC criteria
Grade CT (n = 65) RT (n = 68) P value
Colitis/Proctitis 0.000
0 65(100 %) 34(44.1 %)
1 0(0 %) 23(33.8 %)
2 0(0 %) 10(20.6 %)
3 0(0 %) 1(1.5 %)
4 0(0 %) 0(0 %)
Cystitis 0.000
0 65(100 %) 33(48.5 %)
1 0 (0 %) 25(22.1 %)
2 0(0 %) 9(11.8 %)
3 0(0 %) 0(0 %)
4 0(%) 0(0 %)
Dermatitis 0.00
0 65(100 %) 38(55.9 %)
1 0(0 %) 22(32.4 %)
2 0(0 %) 8(11.8 %)
3 0(0 %) 0(0 %)
4 0(0 %) 0(0 %)
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Fig. 1 Kaplan-Meier survival curves of disease free survival (DFS) at chemotherapy and radiotherapy group
Fig. 2 Kaplan-Meier survival curves of disease free survival (DFS) stratified by depth of stromal invasion. It was the subgroup of patients with
stromal invasion depth at 2/3 to full-thickness that made significant difference at these groups
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treated with chemotherapy after radical hysterectomy
[9, 10] and some data support the clinical usefulness of
chemotherapy as a primary treatment for cervical can-
cer. For example, in Takeshima study, three courses of
bleomycin, vincristine, mitomycin, and cisplatin were ad-
ministered adjuvantly to 30 patients with intermediate-
risk (stromal invasion more than 50 %) and five courses
for high-risk cases. Their treatment results suggest the po-
tential role of adjuvant chemotherapy alone for patients
with cervical cancer [6]. Hosaka M et al. also found that in
patients with intermediate risks chemotherapy has the
equivalent therapeutic effects as RT but with fewer post-
operative complications [11].
However, these reports all evaluated the patients with
combination of intermediate risks. In fact, patients with-
out a combination of intermediate risks, but only one of
the intermediate risks were often encountered in clinical
practice. DSI, for example, was the often encountered
pathology situation. In a retrospective study, Shimada
et al. reported that all 21 of their patients with isolated
DSI after radical hysterectomy and PLND were not ad-
ministered PORT and experienced no recurrence [12].
They suggested that isolated DSI should not be used to
select patients for adjuvant radiation and that DSI could
be excluded as a prognostic factor. But more study
found that the relative risk of recurrence was propor-
tional to the depth of stromal invasion, and 5-year DFS
in patients with an isolated outer one-third invasion
was reported to be about 80 % to 90 % in a GOG study
[13, 14]. However, few studies have evaluated the out-
comes of different adjuvant therapy strategies in this
particular group of patients and it is not certain
whether chemotherapy alone improves the survival and
standard postoperative adjuvant therapy is needed.
In this study we compared the DFS of patients with
deep stromal invasion and received postoperative adju-
vant chemotherapy with patients who received postoper-
ative adjuvant radiation. Contrary to Lee findings that
adjuvant chemotherapy in patients with FIGO stage IB1
and IIA1 cervical cancer and surgically confirmed inter-
mediate risk factors may be effective [7], the Kaplan-
Meier survival analysis in our study demonstrated that
the postoperative recurrence rate was significant reduced
in the chemoradiation group. The DFS were higher in
patients treated with postoperative adjuvant radiation
than in those treated with adjuvant chemotherapy and
differed significantly with survival prolonged DFS 96.2 %
(P = 0.030), indicating that the reduction in recurrence
will certainly benefit a number of patients with this
pathologic factor and patients therefore might benefit
from pelvic irradiation.
Upon further stratification based on invasion depth, the
data showed that patients did demonstrate inferior re-
sponses to chemotherapy compared to chemo radiotherapy
and we found that the recurrence occurred almost in pa-
tients with full-thick invasion, which indicated that women
with full-thick were more likely to develop recurrence. Al-
though these subsets were small, the present results suggest
that full-thick invasion alone might be a definitive indica-
tion for postoperative radiotherapy and patients with full-
thick might be allocated to the postoperative radiotherapy.
Postoperative adjuvant therapy for this subgroup of patients
cannot replaced by chemotherapy alone and the adjuvant
therapy for IB1and IIA1 patients, even not combined with
other intermediate risks, should be tailored according to
stromal deepness status. However, improved DFS at radio-
therapy group observed in our finding may also contributed
to the combined treatment method, as the radiation group
was given concurrent weekly cisplatin as a radiation
sensitizer, the benefit of concurrent chemoradiation over
chemotherapy will remains unclear [15].
It cannot deny the fact that the risk of complications
was higher in patients administered to RT group. A cor-
responding incidence rate of late toxicities was observed
in RT group than in CT group, which was consistency to
previous report study [3]. But no serious toxicity requir-
ing surgical intervention for intestinal obstruction or for-
mation of a fistula, and the frequencies of late toxicities
developed in the RT group in the present study are more
likely to result in early and late complications, such as
gastrointestinal and genitourinary complications, while
only mild to moderate bone marrow depression in
chemotherapy group were significantly observed. How-
ever, as the rate of severe complications have been re-
ported divergent retrospective studies, in stage IB–IIA
cervical carcinoma with acceptable morbidity in many
surgery plus PORT. As a proportion of patients diag-
nosed at younger ages and early disease stages, postoper-
ative RT may extinguish the advantages of surgical
therapy [16, 17]. The risk-to-benefit ratio must always
be considered in determining adjuvant treatment modal-
ity. In order to reduce the morbidity that may be caused
by aggressive multimodality therapy, it seems important
to conduct randomized trials to verify the effectiveness
of these strategy adjuvant therapies may improve sur-
vival but are associated with several adverse effects and
toxicities [18, 19].
In conclusion, the results of the present study strongly
support the use of radiation in patients. However, because
of the non-prospective design of the study, the analysis in
this study suffers from unforeseen biases and we cannot
draw the final conclusion regarding the respective effects
of the two adjuvant treatment modalities on overall sur-
vival. A prospective randomized trial of CT versus RT as
an optional adjuvant therapy to patients is necessary in fu-
ture study to confirm this finding. Treatment strategies
and different protocols of chemotherapy and pelvic radi-
ation are required further with a prospective study.
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Conclusions
Our study indicated postoperative RT administered to pa-
tients with isolated DSI can reduce the risk of locoregional
recurrence and improves the disease-free survival, sug-
gesting that adjuvant postoperative treatment should be
tailored according to stromal deepness status. The find-
ings of this study are important for further investigations.
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